Cravatex Q1FY27 consolidated profit turns positive, revenue up 39%
Cravatex Limited returned to profitability in Q1FY27 with a consolidated net profit of ₹43.81 lakh, reversing a loss of ₹136.77 lakh in the previous year. Consolidated revenue grew 39% YoY to ₹3,222.45 lakh, supported by favorable inventory adjustments. Standalone profit declined slightly to ₹41.08 lakh as revenue remained flat.

*this image is generated using AI for illustrative purposes only.
Cravatex Limited reported a consolidated net profit of ₹43.81 lakh for the quarter ended June 30, 2026, marking a return to profitability after recording a net loss of ₹136.77 lakh in the same period of FY26. This improvement coincided with a 39% year-on-year rise in consolidated revenue from operations to ₹3,222.45 lakh, up from ₹2,312.69 lakh in Q1FY26.
The Board of Directors approved the unaudited standalone and consolidated financial results on August 12, 2026. GPS & Associates served as the statutory auditors, issuing an unmodified limited review report on the statements prepared in accordance with Ind AS. The company also disclosed its quarterly financial results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance
Consolidated total income reached ₹3,662.63 lakh, driven by operating revenue and other income of ₹440.18 lakh. While purchase of stock-in-trade increased to ₹1,799.53 lakh, a favorable change in inventories of stock-in-trade amounting to ₹(202.36) lakh significantly reduced total expenses to ₹3,595.70 lakh.
| Metric: | Q1FY27 (Consolidated): | Q1FY26 (Consolidated): | Change: |
|---|---|---|---|
| Revenue from Operations: | ₹3,222.45 lakh | ₹2,312.69 lakh | +39.3% |
| Total Income: | ₹3,662.63 lakh | ₹2,833.65 lakh | +29.3% |
| Total Expenses: | ₹3,595.70 lakh | ₹2,969.81 lakh | +21.1% |
| Net Profit/(Loss): | ₹43.81 lakh | ₹(136.77) lakh | Turnaround |
| EPS (Basic): | ₹1.70 | ₹(5.29) | N/A |
On a standalone basis, Cravatex reported a net profit of ₹41.08 lakh, compared to ₹44.21 lakh in Q1FY26. Standalone revenue remained flat at ₹144.49 lakh. Other income contributed ₹139.64 lakh to standalone total income, which stood at ₹284.13 lakh.
What the Numbers Show
A notable divergence exists between the standalone and consolidated results regarding inventory management. While the standalone entity reported no change in inventories, the consolidated group recorded a positive adjustment of ₹202.36 lakh in the change in inventories of stock-in-trade. This favorable inventory movement was a key factor in narrowing the gap between total income and total expenses at the group level, enabling the turnaround to profit despite higher employee benefits expense (₹740.54 lakh vs ₹741.92 lakh) and other expenses (₹1,211.98 lakh vs ₹857.77 lakh) compared to the prior year quarter.
Historical Stock Returns for Cravatex
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.84% | -0.93% | 0.0% | 0.0% | 0.0% | 0.0% |
Will Cravatex be able to sustain its profitability in Q2FY27 now that the one-time benefit from favorable inventory adjustments has been realized?
What specific operational strategies or market expansions are driving the 39% year-on-year revenue growth, and are these trends expected to continue?
How does the significant divergence between standalone flat revenue and consolidated revenue growth impact the valuation of the company's subsidiaries versus its core operations?


































